Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R F Schlenk

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Leukemia|April 18, 2002
Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemiaR F Schlenk, F Hartmann, M Hensel, et al.
British Journal of Haematology|March 2, 1999
Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell contentM T Voso, S Hohaus, M Moos, et al.
Leukemia|June 27, 2008
Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemiaM T Voso, S Hohaus, F Guidi, et al.
British Journal of Haematology|December 31, 1997
Successful collection of peripheral blood progenitor cells in patients with acute myeloid leukaemia following early consolidation therapy with granulocyte colony-stimulating factor-supported high-dose cytarabine and mitoxantroneR F Schlenk, H Döhner, M Pförsich, et al.
Leukemia|June 11, 2014
Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remissionJ Versluis, M Labopin, D Niederwieser, et al.
British Journal of Cancer|April 3, 1999
Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancerS Hohaus, L Funk, S Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2020
NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agentsJ Laskin, S V Liu, K Tolba, et al.
Leukemia|December 18, 2009
Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysisL Bullinger, J Krönke, C Schön, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2004
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia IntergroupR F Schlenk, A Benner, J Krauter, et al.
Leukemia|July 20, 2012
Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevanceF G Rücker, A C Russ, S Cocciardi, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Leukemia|April 18, 2002
Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemiaR F Schlenk, F Hartmann, M Hensel, et al.
British Journal of Haematology|March 2, 1999
Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell contentM T Voso, S Hohaus, M Moos, et al.
Leukemia|June 27, 2008
Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemiaM T Voso, S Hohaus, F Guidi, et al.
British Journal of Haematology|December 31, 1997
Successful collection of peripheral blood progenitor cells in patients with acute myeloid leukaemia following early consolidation therapy with granulocyte colony-stimulating factor-supported high-dose cytarabine and mitoxantroneR F Schlenk, H Döhner, M Pförsich, et al.
Leukemia|June 11, 2014
Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remissionJ Versluis, M Labopin, D Niederwieser, et al.
British Journal of Cancer|April 3, 1999
Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancerS Hohaus, L Funk, S Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2020
NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agentsJ Laskin, S V Liu, K Tolba, et al.
Leukemia|December 18, 2009
Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysisL Bullinger, J Krönke, C Schön, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2004
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia IntergroupR F Schlenk, A Benner, J Krauter, et al.
Leukemia|July 20, 2012
Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevanceF G Rücker, A C Russ, S Cocciardi, et al.
Pageof 4